Article Details
Retrieved on: 2021-03-25 16:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The large-cap biopharma announced positive primary results from the Phase 2/3 trial evaluating the fixed-dose combination of relatlimab, ...
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here